alendronate has been researched along with Hypogonadism in 5 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Hypogonadism: Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Denosumab and alendronate showed similar clinical efficacy in the therapy of ADT-related osteoporosis in men with prostate carcinoma; both drugs provided significant improvements in back pain and general health conditions." | 9.24 | Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate. ( Balsano, M; Doria, C; Maestretti, G; Mosele, GR; Scarpa, RM; Solla, F, 2017) |
| " Our results support the long-term administration of alendronate along with testosterone replacement to men with hypogonadism-induced osteoporosis." | 6.71 | Alendronate for osteoporosis in men with androgen-repleted hypogonadism. ( Doolman, R; Eshed, V; Karasik, A; Sela, BA; Shimon, I; Vered, I, 2005) |
| "Denosumab and alendronate showed similar clinical efficacy in the therapy of ADT-related osteoporosis in men with prostate carcinoma; both drugs provided significant improvements in back pain and general health conditions." | 5.24 | Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate. ( Balsano, M; Doria, C; Maestretti, G; Mosele, GR; Scarpa, RM; Solla, F, 2017) |
| " Our results support the long-term administration of alendronate along with testosterone replacement to men with hypogonadism-induced osteoporosis." | 2.71 | Alendronate for osteoporosis in men with androgen-repleted hypogonadism. ( Doolman, R; Eshed, V; Karasik, A; Sela, BA; Shimon, I; Vered, I, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doria, C | 1 |
| Mosele, GR | 1 |
| Solla, F | 1 |
| Maestretti, G | 1 |
| Balsano, M | 1 |
| Scarpa, RM | 1 |
| Morgan Ortiz, F | 1 |
| Meza Mendoza, C | 1 |
| Beltrán Lugo, I | 1 |
| Caballero RodrÃguez, B | 1 |
| Contreras Soto, JO | 1 |
| Ringe, JD | 1 |
| Shimon, I | 1 |
| Eshed, V | 1 |
| Doolman, R | 1 |
| Sela, BA | 1 |
| Karasik, A | 1 |
| Vered, I | 1 |
| Tanimoto, K | 1 |
| Okubo, Y | 1 |
| Harada, C | 1 |
| Saito, H | 1 |
| Sata, A | 1 |
| Nishikawa, A | 1 |
| Ohwada, R | 1 |
| Tsuiki, M | 1 |
| Yamamoto, M | 1 |
| Hashimoto, E | 1 |
| Sato, K | 1 |
| Takano, K | 1 |
1 review available for alendronate and Hypogonadism
| Article | Year |
|---|---|
[Osteoporosis in men].
Topics: Alendronate; Androgens; Calcium Channel Blockers; Diagnosis, Differential; Etidronic Acid; Fractures | 2003 |
2 trials available for alendronate and Hypogonadism
| Article | Year |
|---|---|
Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Denosumab; Double-Blind Meth | 2017 |
Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
Topics: Adult; Aged; Alendronate; Amino Acids; Androgens; Biomarkers; Bone Density; Bone Density Conservatio | 2005 |
2 other studies available for alendronate and Hypogonadism
| Article | Year |
|---|---|
[Resistant ovary syndrome. Case report].
Topics: Adolescent; Alendronate; Bone Density Conservation Agents; Estrogens; Female; Hormone Replacement Th | 2011 |
Latent hypoparathyroidism in an osteoporotic patient with multiple endocrinopathies and secondary hemochromatosis due to multiple blood transfusions, unmasked by alendronate and glucocorticoid at adrenal crisis.
Topics: Adrenal Glands; Adult; Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcium; Diab | 2008 |